Hauke Smidt is a Personal Professor at Wageningen University & Research, affiliated with the Molecular Ecology group within the Faculty of Veterinary Medicine and Animal Sciences. His research focuses on microbial ecology, particularly gut microbiota dynamics, antibiotic resistance, environmental microbiology, and the One Health framework. Smidt has supervised over 50 PhD students and contributed to 519 publications, including studies on microbiome resilience, fermented food impacts, and bioremediation strategies. Education and affiliations include leadership roles in projects addressing antimicrobial resistance, pig health, and drinking water microbiology. His work spans collaborations across Europe and Asia, with notable contributions to understanding microbial community responses to environmental stressors and dietary interventions. Smidt is actively involved in public outreach, as seen in media contributions discussing microbiome research and health benefits. Key projects include aquifer treatment for drinking water, microbiome simulation models, and combating plant pathogens. His awards and recognition are not explicitly listed, but his extensive publication record and project leadership highlight significant academic impact.
Dr. Keith Alexander Sharkey is a Professor in the Department of Physiology and Pharmacology at the Cumming School of Medicine, University of Calgary. He is also a Full Member of both the Hotchkiss Brain Institute and The Calvin, Phoebe and Joan Snyder Institute for Chronic Diseases. Dr. Sharkey has been at the University of Calgary since his appointment as Assistant Professor in 1990, dedicating his career to understanding the neural control of the gastrointestinal tract. From 2005-2021, he held the Crohn's and Colitis Canada Chair in Inflammatory Bowel Disease Research, demonstrating his longstanding commitment to advancing knowledge in gastrointestinal sciences. Dr. Sharkey's educational journey began with a BSc (Hons) in Nutrition from the University of London in 1981, followed by a PhD in Physiology from the University of Liverpool in 1985. After completing postdoctoral training in Hungary, the UK, and Canada, he joined the University of Calgary faculty in 1990, where he has remained throughout his distinguished academic career. Dr. Sharkey's research program centers on understanding the physiology and pathophysiology of the neural control of the gastrointestinal tract and brain-gut interactions in health and disease. His laboratory investigates two main areas: the role of the endocannabinoid system in regulating GI motility and intestinal barrier function, and the physiology of the enteric nervous system in controlling motility and barrier function. His work employs state-of-the-art approaches including live cell imaging and molecular genetics. Recent publications show his expanding interest in connections between gut function and neurodegenerative conditions like ALS, with multiple 2024-2025 papers examining sexual dimorphism in disease processes and gut-brain axis mechanisms. Fellow, Royal Society of Canada (2024) Cumming School of Medicine's van de Sande Distinguished Achievement Award for Mentorship (2021) Distinguished Research Award, American Physiological Society (2021) Finkelstein Award for Excellence, Crohn's and Colitis Canada (2016) Fellow, Canadian Academy of Health Sciences (2015) Fellow, Canadian Association of Gastroenterology (2015) Killam Annual Professor Award, University of Calgary (2013) Dr. Sharkey has mentored numerous students throughout his career, as evidenced by his 2021 Mentorship Award. His research is supported by significant funding, including a CIHR Foundation grant exploring how enteric nerves and glia maintain intestinal homeostasis. He has also participated in university strategic initiatives focused on Brain and Mental Health (2015-2021) and Infections, Inflammations and Chronic Diseases (2015-2021), demonstrating his interdisciplinary approach. The Sharkey Lab provides a safe, inclusive, and diverse research environment that encourages open scientific exchange from diverse viewpoints. His laboratory is actively engaged in multiple collaborative projects, including investigations with UBC Okanagan on diet and probiotics targeting the gut-brain metabolic interactome, and with University of Calgary colleagues studying gut microbiota's role in ALS. Dr. Sharkey continues to advance our understanding of neural mechanisms controlling gastrointestinal function with upcoming courses scheduled for Fall 2024 and Winter 2025.
Björn Pasternak is a Research Professor leading the Pharmacoepidemiology group at the Department of Medicine, Solna, Karolinska Institutet. His team specializes in large-scale registry studies focused on adverse drug effects, with research programs in pediatric pharmacoepidemiology, safety of diabetes medications, and rapid assessment of drug safety concerns. The group leverages high-quality epidemiological methods to inform evidence-based clinical decisions. Pasternak's research interests span pharmacoepidemiology, drug safety, diabetes outcomes, cardiovascular risk, and perinatal health. His work utilizes nationwide registries to evaluate real-world drug effects, socioeconomic disparities in treatment, and long-term outcomes of chronic therapies. Key focuses include GLP-1 receptor agonists, SGLT2 inhibitors, antibiotic use in pregnancy, and opioid safety. Recent publications demonstrate strong emphasis on Scandinavian cohort studies of diabetes medications (GLP-1 agonists, SGLT2 inhibitors) and their associations with thyroid cancer, liver events, intestinal obstruction, and cardiovascular/renal outcomes. Other trends include perinatal pharmacovigilance (antibiotics, acid-suppressive drugs) and neurodegenerative risks in athletes.
Manuel R. Amieva is a Professor at Stanford University School of Medicine , holding joint appointments in Pediatrics - Infectious Diseases and Microbiology & Immunology . He is also a member of the Maternal & Child Health Research Institute (MCHRI) . His clinical practice at Stanford Medicine Children's Health focuses on pediatric infectious diseases. Education: Medical Education: Stanford University School of Medicine (1997) Fellowship: Stanford University Pediatric Infectious Disease Fellowship (2004) Internship & Residency: Stanford Health Care at Lucile Packard Children's Hospital (1998-1999) Dr. Amieva's research investigates host-pathogen interactions at epithelial barriers, with specific expertise in Helicobacter pylori , Listeria monocytogenes , Salmonella enterica , and Staphylococcus aureus . His lab develops innovative organoid culture systems with controlled polarity to study microbial colonization and oncogenic mechanisms. Key discoveries include: H. pylori's manipulation of epithelial junctions via the CagA protein Listeria's exploitation of cell extrusion sites for invasion Staphylococcus toxin interactions with adherens junctions Gastric stem cell activation by pathogens Recent publication trends show continued leadership in infectious disease mechanisms (2020-2025), with a focus on: Pathogen-specific epithelial breach strategies Organoid modeling of viral/bacterial interactions Redox-dependent host factor regulation Single-cell spatial transcriptomic analyses Multi-institutional educational frameworks His scientific collaborations span disciplines including: Gastric cancer genomics initiatives COVID-19 lung infection models Stem cell-microbe interactions Medical education reform projects Dr. Amieva maintains active clinical research while mentoring students in both the Microbiology & Immunology and Pediatrics programs. His lab at Stanford employs advanced 3D confocal microscopy and organ-on-a-chip technologies to visualize epithelial colonization dynamics.
Jürgen König is a full professor at the Department of Nutritional Sciences , University of Vienna, leading the Research Professorship Specialized Human Nutrition . His work bridges psychological and physiological dimensions of eating behavior, with additional focus on population-level nutritional assessment in Austria. Academic Rank: Professor Department: Nutritional Sciences Research Focus: Hunger/satiety mechanisms, Public health nutrition, Food safety Key research themes include: Psychological drivers of eating behaviors (stress, food craving, sensory cues) Physiological regulation of nutrient homeostasis National nutrition surveys assessing dietary patterns Caloric restriction and metabolic adaptation Child and adolescent hydration/nutrition policies Recent publications highlight: Mechanistic studies on caloric restriction effects (2025) Pandemic impacts on school nutrition (2024) Global obesity/diabetes trends analysis (2024) Behavioral nudging in food selection (2024) Microbiota's role in dietary interventions (2023) Contact: juergen.koenig@univie.ac.at | Sekretariat: sekretariat.ew@univie.ac.at
Dr. Michael Baym is an Associate Professor of Biomedical Informatics at Harvard Medical School with affiliate appointments in Microbiology and the Laboratory of Systems Pharmacology, and as an Associate Member of the Broad Institute. He leads the Baym Lab, which studies microbial evolutionary genomics and antibiotic resistance through a hybrid of experimental, computational, and theoretical approaches. His research focuses on: Antibiotic Resistance Evolution and practical interventions Mobile Genetic Elements (plasmids, phages, transposons) Computational Genomic Algorithms for big data analysis Synthetic Biology tools and technologies Key recent publications explore phage discovery systems , phylogenetic compression of microbial genomes, and RNA-guided gene drives in plasmids. His work is supported by multiple NIH/NIGMS and NSF grants including a MIRA award. Scientific honors include: Packard Fellowship (2018) Pew Biomedical Scholarship (2020) Sloan Research Fellowship (2020) A. Clifford Barger Excellence in Mentoring Award (2021) SSQBio Mentorship Award (2022) The lab actively trains PhD students and postdoctoral fellows with alumni occupying academic and industry positions globally. Current team members include researchers from interdisciplinary backgrounds working at the intersection of experiment, computation, and theory .
Jethro Johnson is an Innovation Track Principal Investigator at the Kennedy Institute of Rheumatology and Deputy Director of the Oxford Centre for Microbiome Studies (OCMS) at the University of Oxford. His work integrates computational genomics and microbiome research to explore host-microbiome interactions in health and disease. PhD in Nutritional Ecology (University of Auckland, 2012) MRC Career Development Fellowship Former postdoctoral researcher at Jackson Laboratory for Genomic Medicine Research focuses on: Mechanistic understanding of gut microbiome impacts on metabolic diseases Multi-omic data integration for host-microbiome studies Computational approaches to microbiome analysis Methodological developments in 16S rRNA gene profiling Publications emphasize microbiome-disease associations, methodological innovations, and computational genomics applications across human and mouse models. Key themes include metabolic dysfunction, immune interactions, and microbial diversity analysis. Scientific recognition includes: MRC Career Development Fellowship in Computational Genomics As OCMS Deputy Director, he contributes to advancing microbiome research infrastructure and collaborative projects while leading his own computational genomics group at the Kennedy Institute.
Kristina Schoonjans is an Associate Professor at EPFL’s School of Life Sciences, where she leads the Laboratory of Metabolic Signaling (UPSCHOONJANS). Her research focuses on the molecular mechanisms of bile acid signaling, nutrient sensing, and intermediary metabolism, particularly in the context of metabolic disorders such as obesity, fatty liver disease, and cancer. She investigates how the liver-gut-brain axis integrates metabolic signals through nuclear receptors and mitochondrial dynamics. Her research interests include: Bile acid signaling and its role as a hormonal regulator Nutrient and metabolite sensing in energy homeostasis Intermediary metabolism and metabolic disorders Role of nuclear receptors (e.g., TGR5, LRH-1) in liver, gut, and adipose tissue Mitochondrial dynamics and fission in metabolic regulation Organoid models for studying liver and intestinal metabolism Systems genetics using BXD mouse populations The most recent articles highlight a strong focus on bile acid signaling, particularly through TGR5 and LRH-1, in regulating metabolic health. Themes include the conversion of white fat to beige fat (beiging), hepatic tumorigenesis, mitochondrial fission, and the use of organoid and genetically engineered mouse models. There is a consistent emphasis on translational applications for obesity, fatty liver disease, and cancer. Scientific honors include: Windaus Prize from the Dr. Falk Foundation (2010, shared with Johan Auwerx) for the discovery of the signaling/endocrine function of bile acids Prof. Schoonjans actively supervises PhD students and has advised numerous doctoral candidates who have since completed their theses. Her lab is supported by multiple grants from Swiss and international funding agencies, including the Swiss National Science Foundation, EPFL, CONACYT, and the Foundation for Health and Education. She teaches in several doctoral programs at EPFL, including Life Sciences Engineering, and contributes to education through the SSV and EDBB/EDCB/EDMS-ENS programs. The Schoonjans Lab brings together scientists, doctoral assistants, and technicians working on projects related to metabolic signaling. The team uses advanced techniques such as genetically modified mouse models, organoid cultures, and multi-omics (metabolomics, proteomics, transcriptomics) to study the liver-gut and brain-liver axes. The lab has a strong track record of high-impact publications and collaborations with institutions worldwide.
Elin Org is a Professor of Microbiomics at the University of Tartu's Institute of Genomics, where she also serves as Head of the Estonian Genome Centre and Vice Director of the Institute. Her academic career spans over two decades with significant contributions to microbiome and genomic research. Education: PhD in Genetics, University of Tartu (2006) Master's Degree in Molecular Biotechnology and Biomedicine, University of Tartu (2000) Bachelor's Degree, University of Tartu (1997) Classical Singing, Heino Eller Tartu Music School (1996) Professor Org's research primarily focuses on the intricate relationships between host and gut microbiota and their influence on metabolism and common complex diseases. Her work bridges microbiomics, genomics, and complex disease research, with particular emphasis on understanding how gut microbiome composition affects human health. She has pioneered research connecting long-term antibiotic usage with microbiota-dependent effects and has made significant contributions to understanding the role of gut microbiome in conditions such as gestational diabetes, endometriosis, and polycystic ovary syndrome. Her approach integrates advanced computational methods with comprehensive health data to uncover causal relationships in microbiome research. Her recent publications demonstrate a strong trend toward integrating microbiome data with extensive digital health metrics, using machine learning approaches to identify microbial predictors of health outcomes. This work is increasingly focused on translating microbiome research into clinical applications for disease prediction and personalized medicine approaches, particularly in the context of the Estonian Biobank initiative. Major Scientific Recognition: 2025 National Science Award in medical and health sciences 2023 and 2022: Recognized among the world's top 1% most cited researchers by Clarivate Analytics 2020: Member of AcademiaNet, a portal for top female researchers 2017: EMBO Installation grant 2013: Marie Curie International Outgoing Fellowship Professor Org has secured substantial research funding as principal investigator for multiple significant projects, including 'DISCERN - Discovering the causes of three poorly understood cancers in Europe' (€245,466, European Commission) and 'Improving colorectal cancer screening and prediction using microbiome-based biomarkers' (€760,450, Estonian Research Council). She has served as an opponent for numerous PhD theses across European institutions, contributing to the development of emerging researchers in her field. As Head of the Estonian Genome Centre, Professor Org leads a multidisciplinary research team that plays a crucial role in Estonia's transition from biobanking to personalized medicine applications. She is actively involved in international collaborations through COST networks including INFOGUT (focused on in vitro colon models) and ML4Microbiome (statistical and machine learning techniques in human microbiome studies), positioning her at the forefront of global microbiome research initiatives.
John F. Brooks II is an Assistant Professor in the Department of Molecular Biology at Princeton University, where he leads the Brooks Lab. His research focuses on the circadian regulation of host-microbe dynamics, particularly how the circadian clock interfaces with the immune system to maintain gut microbiome harmony. Education: Ph.D., Northwestern University Feinberg School of Medicine, Walter S. and Lucienne Driskill Graduate Training Program in Life Sciences B.S., University of Michigan, Microbiology Research Interests: Dr. Brooks investigates how the circadian clock controls the rhythmic secretion of antimicrobial proteins (AMPs) in the small intestine and how persistent infections override these rhythms to sustain AMP production. His work integrates cell and molecular immunology, mouse genetics, and genomics to uncover mechanisms of circadian-immune crosstalk. This research has broad implications for disorders linked to circadian disruption, including obesity, diabetes, and chronic gut inflammation. Recent Publication Trends: His recent publications emphasize the coordination between microbial signals and host circadian rhythms in regulating innate immunity. Key themes include diurnal patterns in immune function, microbiota-driven immune modulation, and the physiological consequences of circadian misalignment in infection and disease. Scientific Awards: Pew Scholar in the Biomedical Sciences (2024) Advising and Grants: Dr. Brooks mentors graduate students and postdoctoral researchers, including Talia Akoh-Arrey and Urbashi Basu. His lab has received significant funding, notably the Pew Biomedical Scholars Award, supporting innovative research at the intersection of immunology, microbiology, and chronobiology. Labs and Teams: The Brooks Lab at Princeton employs interdisciplinary approaches to study host-microbe interactions. The team collaborates with experts in immunology and circadian biology, including Lora Hooper and Joseph Takahashi, to advance understanding of temporal regulation in immunity.
Professor Mirko Trajkovski leads the Laboratory of Metabolic Diseases at the Faculty of Medicine, University of Geneva. He completed his PhD at the International Max Planck School in Dresden (2005), followed by postdoctoral research at ETH Zurich, before establishing his lab at University College London (2012) and moving to Geneva (2013). His work focuses on adipose tissue plasticity , gut microbiota , and their roles in obesity , diabetes , and insulin resistance . Swiss National Science Foundation Professor (2014) ERC Starting Grant (2014) & Consolidator Grant (2019) Dr Walter Seipp Prize & Carl Gustav Carus Prize (2005) His lab investigates fat browning mechanisms , microbiota-host communication , and multi-tissue metabolic regulation using in vivo , in vitro , and human cohort approaches. Recent publications emphasize microbiome-based therapies , temperature effects on metabolism , and gut-bone-adipose crosstalk . Current advisees include PhD student Silas Kieser, with past members like Jing Xue, Salvatore Fabbiano, and Claire Chevalier contributing to immuno-metabolism and microbial engineering projects.
Dame Fiona Powrie is a Professor of Musculoskeletal Sciences at the University of Oxford and Director of the Kennedy Institute of Rheumatology . She leads the Mucosal Immunology Research Group and serves as Director of the Oxford Centre for Microbiome Studies (OCMS) and Cluster Lead in the MRC National Mouse Genetics Network Microbiome Cluster . Roles: Director of Kennedy Institute, Professor, Research Group Leader Relevant Affiliations: Wellcome Trust Governor (2018–present), Deputy Chair (2022), Royal Society Fellow (2011) Research Interests : Fiona specializes in the interplay between the intestinal microbiota and the host immune system, focusing on how dysregulation leads to inflammatory bowel disease (IBD) . Her work has elucidated the role of regulatory T cells in maintaining gut homeostasis and identified the IL-23 pathway as critical in chronic intestinal inflammation. Current efforts aim to translate these findings into clinical therapies for IBD patients. Scientific Awards and Fellowships : Ita Askonas Award (European Federation of Immunological Societies) Louis-Jeantet Prize for Medicine (2012) Honorary Lifetime Membership (British Society of Immunology, 2021) Fellow of the Royal Society (2011), EMBO (2013), Academy of Medical Sciences (2014) International Fellow of the National Academy of Sciences (2020) Advising and Leadership : Fiona leads the Mucosal Immunology group at the Kennedy Institute, mentors researchers, and contributes to national and international scientific governance. She has been instrumental in advancing microbiome and immunology research through leadership roles at the Oxford Centre for Microbiome Studies and the MRC National Mouse Genetics Network . Labs and Teams : Fiona's research group at the Kennedy Institute of Rheumatology investigates mucosal immunity and microbiome interactions, combining experimental and clinical approaches to address inflammatory diseases.
Dr. Rebecca Clark is an Associate Professor in the Department of Biosciences at Durham University. Her research focuses on understanding intestinal function in health and disease using the Drosophila model. She investigates how the intestinal epithelium balances barrier function, nutrient absorption, microbial symbiosis, and cell turnover, particularly during aging and disease states. Key research questions include mechanisms of intestinal barrier failure and the interplay between nutrition and intestinal homeostasis. Her work integrates genetic, microbiological, and physiological approaches to explore aging-related pathologies. Current projects aim to identify molecular pathways linking intestinal health to longevity. Supervised postgraduate students include Ale Acevedo Marcelin, Beñat Yanez, and Fanila Shahzad. Dr. Clark’s lab uses Drosophila as a model system due to its powerful genetic tools and evolutionary relevance. Research has implications for understanding human conditions such as inflammatory bowel disease and age-related metabolic disorders. Recent findings highlight microbiota-independent aging mechanisms and the role of tricellular junctions in stem cell regulation. No scientific awards are explicitly listed in the provided materials. Her research has been published in journals like Cell , Nature Cell Biology , and Proceedings of the National Academy of Sciences .
Frida Hållenius is an Associate Professor and Senior Lecturer in Molecular Nutrition at the Division of Food and Pharma, Faculty of Engineering (LTH), Lund University. She is a key member of the LTH Profile Area: Food and Bio and leads or actively participates in multiple research projects exploring the role of diet and gut microbiota in human health. Associate Professor in Molecular Nutrition Senior Lecturer, Division of Food and Pharma Faculty of Engineering (LTH), Lund University Principal Investigator, Gut Microbiome Laboratory (GML) Active researcher in 3 ongoing projects, including NeuroFood and ScanOats Her research is centered on host-microbiota interactions, particularly how dietary components, probiotics, and polyphenols influence gut health, inflammation, metabolic diseases, and neuroinflammation. Her work bridges nutrition, microbiology, and neuroscience, with a strong focus on preventive strategies for lifestyle-related diseases such as obesity, diabetes, and Alzheimer’s disease. She employs both animal models (e.g., C57BL/6, Apoe-/- mice) and human-relevant in vitro systems to study dietary interventions. The recent trends in her publications highlight a strong focus on the gut-brain axis, the impact of Nordic berries and legumes on microbiota and metabolic health, and the use of advanced models like 3D intestinal tissue. Her work often involves interdisciplinary collaboration and contributes to multiple UN Sustainable Development Goals, particularly those related to good health and well-being. Scientific Awards: No specific awards mentioned in the provided text. She has supervised several junior researchers and students, including research students and assistants, and is actively involved in grant-funded research projects from FORMAS and private foundations. She leads the Gut Microbiome Laboratory (GML), a collaborative research environment focused on understanding how diet shapes the gut microbiome and influences disease pathways. Her leadership in projects like NeuroFood and those targeting Alzheimer’s disease underscores her commitment to translational nutritional science.
Professor David Ackerley (Victoria University of Wellington) is a leading microbiologist and enzyme engineer specializing in directed evolution of bacterial enzymes for biotechnological applications. As Biotechnology Programme Director since 2006, he lectures in foundational courses like BTEC101 and BTEC201. Academic rank: Professor of Biotechnology Institutional affiliation: Victoria University of Wellington Research focus areas: Microbial Biotechnology, Drug Discovery, Synthetic Biology His research employs Darwinian evolutionary principles to engineer enzymes with enhanced activities, particularly targeting non-ribosomal peptide synthetases and nitroreductases for antibiotic development and cancer therapy. Recent work explores metagenomic domain substitution in pyoverdine biosynthesis and Purpuramine R from marine sponges. Key publications demonstrate innovations in metagenomic library construction , CRISPR screening for regeneration genes, and structural characterization of engineered enzymes. His team has developed NTR 2.0 , a high-efficacy nitroreductase for targeted cell ablation. Current research projects include: Clean solutions from dirty genes: Plastic-degrading enzyme discovery Engineering enzymes for CAR T-cell-chemotherapy synergy Repurposing niclosamide against Gram-negative superbugs Grants from the Health Research Council of New Zealand, Royal Society of New Zealand, and Cancer Society of NZ support his work. Collaborations span biomedical research, synthetic biology, and environmental applications.
